Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

Brian Feagan, William Sandborn, Bosny Pierre-Louis, Christopher Fourment, Maria Abreu

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))'. Together they form a unique fingerprint.